All In Biotech

Drug Trial Radar · NCT06886516

Apixaban in Thrombocytopenia

ADAPTiON: Apixaban Dose Adjustment in Patient With Thrombocytopenia in ONcology

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Feb 28, 2025

Primary completion

Jul 1, 2027

Study completion Jul 1, 2029

Sponsor

Lead sponsor
Rushad PatellAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)

Conditions

  • Deep Vein Thrombosis
  • Pulmonary Embolism and Thrombosis
  • Thrombocytopenia
  • Recurrent Venous Thromboembolism

Interventions

  • ApixabanDrug

    A factor Xa inhibitor, 2.5 and 5 mg tablets, by mouth per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study EnrollmentTime frame: Up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.